Your Messages Inbox
Your Article Summary
See Latest ArticlesUCB"s Cimzia Approved in the U.S. for Adult Patients Suffering from Moderate to Severe Rheumatoid Arthritis
-- Enzon to receive royalties for PEGylation technology--
Enzon Pharmaceuticals, 05/15/09
Enzon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia, for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Cimzia, is a PEGylated anti-TNFa. The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon's PEGylation technology, including PEG-INTRON, Macugen, and Pegasys.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/11/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Article Search
Sponsor